Phase 3 Type 2 Diabetes Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Adults aged 18 years or older at the time of signing the consent form.
- People with a body mass index (BMI) between 18.0 and 35.0 — a measure of body weight relative to height — falling within this range on either end.
- People who have been clinically diagnosed with type 2 diabetes before the screening visit.
- People whose blood sugar control measure (called HbA1c) is between 7.5% and 9.0%, as tested by the trial's central laboratory on the day of screening.
- People who have been taking a stable dose of diabetes medications — such as oral diabetes tablets, insulin, or GLP-1 medications (for example, exenatide or liraglutide) — for at least 3 months before screening.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- Women who are pregnant, breastfeeding, planning to become pregnant, or who are able to become pregnant and are not using a highly effective form of contraception.
- People who are expected to start or change a medication (for more than 14 days in a row) that is known to affect weight or blood sugar, such as orlistat, thyroid hormones, or steroid medications taken throughout the body.
- People who have had an episode of diabetic ketoacidosis (a serious diabetes complication) within the 90 days before screening, as reported by the person or noted in their medical records.
- People who have had pancreatitis (inflammation of the pancreas), either short-term or long-term, within the 180 days before screening.
- People who have had a heart attack, stroke, hospitalisation for severe chest pain (unstable angina), or a temporary stroke-like episode (transient ischaemic attack) within the 180 days before screening.
- People with severe heart failure classified as New York Heart Association Class IV at the time of screening.
- People with uncontrolled or potentially unstable damage to the back of the eye related to diabetes (diabetic retinopathy or maculopathy), as confirmed by an eye examination within 90 days before screening or between screening and the start of the trial (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Wei-fen Xie, Prof., Shanghai Changzheng Hospital
Phone: +862181886824
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Where this trial is recruiting
Primary endpoints
Number of treatment emergent adverse events; Change in glycated haemoglobin (HbA1c)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.